Literature DB >> 10897334

Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status.

J R Flavell1, K R Baumforth, D M Williams, M Lukesova, J Madarova, V Noskova, J Prochazkova, D Lowe, Z Kolar, P G Murray, P N Nelson.   

Abstract

BACKGROUND: In vitro the Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP-1) has been shown to upregulate expression of matrix metalloproteinase 9 (MMP-9), a member of a family of zinc dependent endopeptidases that is believed to facilitate tumour invasion and metastasis by degradation of the extracellular matrix. AIM: To test whether the expression of MMP-9 in Hodgkin's disease correlates with EBV status and survival and to investigate whether LMP-1 expression affects MMP-9 concentrations in the Hodgkin's disease cell line, L428.
METHODS: MMP-9 expression was measured by means of immunohistochemistry in a series of Hodgkin's disease tumours and this expression was correlated with EBV status and survival. The influence of LMP-1 on MMP-9 expression was also investigated in the Hodgkin's disease cell line, L428.
RESULTS: MMP-9 expression was demonstrated in the malignant Hodgkin and Reed-Sternberg cells of all (n = 86) formalin fixed, paraffin wax embedded Hodgkin's disease tumours examined. Although the intensity of MMP-9 immunostaining varied between cases, there was no correlation between MMP-9 expression and EBV status or survival. MMP-9 expression was also detected in a variety of non-malignant cells, including fibroblasts. MMP-9 was detected by zymography in the L428 and KMH2 Hodgkin's disease cell lines, whereas low or undetectable amounts of MMP-9 were found in the L591 Hodgkin's disease cell line. Induction of LMP-1 expression in the Hodgkin's disease cell line L428 did not result in a detectable increase in the values of MMP-9 as measured by zymography.
CONCLUSIONS: These results demonstrate that MMP-9 is consistently expressed by the Hodgkin and Reed-Sternberg cells of Hodgkin's disease tumours and by the Hodgkin's disease cell lines, L428 and KMH2. However, this expression does not appear to be related either to LMP-1 values or to survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897334      PMCID: PMC1186921          DOI: 10.1136/mp.53.3.145

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  29 in total

1.  Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.

Authors:  S Henderson; M Rowe; C Gregory; D Croom-Carter; F Wang; R Longnecker; E Kieff; A Rickinson
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

2.  Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas.

Authors:  A E Kossakowska; S J Urbanski; D R Edwards
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

Review 3.  Conclusions from Hodgkin-derived cell lines.

Authors:  H Burrichter; M Schaadt; V Diehl
Journal:  Cancer Treat Res       Date:  1989

4.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

5.  Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease.

Authors:  G Pallesen; S J Hamilton-Dutoit; M Rowe; L S Young
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

6.  Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis.

Authors:  C D Gregory; C Dive; S Henderson; C A Smith; G T Williams; J Gordon; A B Rickinson
Journal:  Nature       Date:  1991-02-14       Impact factor: 49.962

7.  Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines.

Authors:  H G Drexler; B F Leber; J Norton; J Yaxley; E Tatsumi; A V Hoffbrand; J Minowada
Journal:  Leukemia       Date:  1988-06       Impact factor: 11.528

8.  Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications.

Authors:  V Diehl; M Pfreundschuh; C Fonatsch; H Stein; M Falk; H Burrichter; M Schaadt
Journal:  Cancer Surv       Date:  1985

9.  Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease.

Authors:  P G Murray; L S Young; M Rowe; J Crocker
Journal:  J Pathol       Date:  1992-01       Impact factor: 7.996

10.  Hodgkin and sternberg-reed cell antigen(s) detected by an antiserum to a cell line (L428) derived from Hodgkin's disease.

Authors:  H Stein; J Gerdes; H Kirchner; M Schaadt; V Diehl
Journal:  Int J Cancer       Date:  1981-10-15       Impact factor: 7.396

View more
  3 in total

1.  Matrix metalloproteinase-9 is consistently expressed in Hodgkin/Reed-Sternberg cells and has no impact on survival in patients with Epstein-Barr virus (EBV)-related and non-related Hodgkin lymphoma in Brazil.

Authors:  Eni M Souza; Otávio C G Baiocchi; Maria A Zanichelli; Antonio C Alves; Marianne G Assis; Joyce M K Silva; Cristine Dobo; José S R Oliveira
Journal:  Med Oncol       Date:  2011-09-16       Impact factor: 3.064

2.  Immunohistochemical approach to the pathogenesis of clinical cases of bovine Herpesvirus type 5 infections.

Authors:  Tereza C Cardoso; Heitor F Ferrari; Andrea F Garcia; Livia C Bregano; Alexandre L Andrade; Adriana Hc Nogueira
Journal:  Diagn Pathol       Date:  2010-09-10       Impact factor: 2.644

3.  Matrix metalloproteinase-9 expression by Hodgkin-Reed-Sternberg cells is associated with reduced overall survival in young adult patients with classical Hodgkin lymphoma.

Authors:  Antonio Hugo Campos; Jose Vassallo; Fernando Augusto Soares
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.